| Identification | Back Directory | [Name]
MLN3126 | [CAS]
628300-71-0 | [Synonyms]
MLN3126
Benzenesulfonamide, N-[4-chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl]-4-(1-methylethoxy)- | [Molecular Formula]
C21H19ClN2O5S | [MOL File]
628300-71-0.mol | [Molecular Weight]
446.9 |
| Chemical Properties | Back Directory | [Boiling point ]
696.8±65.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
6.85±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC50 value of 6.3 nM for calcium influx[1]. | [in vivo]
MLN3126 (2.5% w/w; p.o.) decreases colonic level of IFN-γ, largely produced by T cells[1].
MLN3126 (0.05, 0.25 and 1% (w/w); p.o.) has the potential activity for alleviating inflammatory bowel disease (IBD)[1]. | Animal Model: | Activated T cell transferred colitis mouse model[1] | | Dosage: | 0.05, 0.25 and 1% (w/w) (around 4 g/day)
| | Administration: | Oral gavage; 21 days | | Result: | Blocked CCR9/CCL25 interaction by inhibiting migration of T cells to the colon and resulted in the amelioration of colitis. |
| [storage]
Store at -20°C | [References]
[1] Igaki K, et al. MLN3126, an antagonist of the chemokine receptor CCR9, ameliorates inflammation in a T cell mediated mouse colitis model. Int Immunopharmacol. 2018 Jul;60:160-169. DOI:10.1016/j.intimp.2018.04.049 |
|
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|